Epinephrine Recalled Nationwide Over Glass and Plastic Particles, Health Risks

Vials of a drug that hospitals rely on to treat severe allergic reactions have been pulled from shelves across the United States after the manufacturer found glass and plastic particles inside them.

American Regent, Inc. announced a voluntary nationwide recall of three lots of Epinephrine Injection, USP 30 mg/30 mL on 3 September 2026, after customers reported vials that were leaking and cracked.

The company's investigation then identified foreign particles in the product, and its recall notice warns that injecting those particles into a vein can block blood vessels, damage organs and potentially cause death. American Regent said it had received no reports of adverse events related to the recall.

What the Recall Notice Identifies Inside the Vials

The problem began with the containers rather than the drug. According to the company announcement posted by the Food and Drug Administration, American Regent received customer complaints about leaking and cracked vials, resulting in a lack of assurance that the contents remained sterile.

The investigation that followed identified particulate matter in the product. American Regent said the materials included nylon, cellulosic material, acrylic, polyethylene and glass.

The risk statement sets out what those particles can do. American Regent warns that intravenous administration of the affected product may lead to serious adverse health consequences because particulate matter can cause blockage and clotting in blood vessels, cutting off blood flow to vital organs. The notice states that this can lead to a life-threatening blood clot in the lungs, known as a pulmonary embolism, and cause permanent organ damage or death.

The company lists further hazards. Particles may cause local vein irritation, an inflammatory reaction, aggravation of pre-existing infections and allergic reactions, according to the notice. Cracked vials are treated as a separate danger because a compromised container can lose sterility and allow contamination, which the company says poses a serious risk to patients.

The Three Lots Affected and Where They Went

Every recalled unit carries the same National Drug Code, 0517-3030-01, and the three lot numbers are 25128L1C0, 25280L1C0 and 26108L1C0. All three were distributed nationwide across the United States, and the recall reaches the consumer level.

The distribution windows stretch across almost a year. Lot 25128L1C0 was shipped between 4 September 2025 and 18 December 2025 and expired in August 2026. Lot 25280L1C0 was shipped between 16 December 2025 and 17 April 2026 and expires in October 2026. Lot 26108L1C0 was shipped between 15 June 2026 and 31 July 2026 and expires in July 2027.

American Regent is writing to distributors and customers to arrange returns and replacements. The notice instructs distributors, retailers and healthcare facilities holding the affected product to stop using it and either return it to the place of purchase or discard it. Patients who have the product are told to stop using it and contact their doctor or healthcare provider.

The company has published several contact routes. Its customer service line is 800-645-1706 for returns, replacements and credit, its pharmacovigilance line is 800-734-9236 for reporting adverse events, and product quality complaints and medical questions can be directed to 888-354-4855.

Why This Is Not the Auto-Injector in Your Bag

A distinction matters here that the word epinephrine alone does not convey. The recalled product is a 30 mL multiple-dose vial of clear, colourless sterile solution containing 1 mg/mL, and the notice states that it may be administered intravenously, intramuscularly or subcutaneously under the direction of a physician.

Prescription auto-injectors are a different product and are not included in this recall. The notice covers three lots of one presentation of one injectable medicine, identified by a single National Drug Code, so anyone holding a device rather than a vial can check the packaging and determine whether it is affected.

The clinical uses listed explain the concern. Epinephrine Injection, USP is indicated for the emergency treatment of Type I allergic reactions, including anaphylaxis caused by insect stings or bites, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic and exercise-induced anaphylaxis.

The notice also lists a second indication: raising mean arterial blood pressure in adult patients with hypotension associated with septic shock.

The Severity Ranking the FDA Has Not Yet Assigned

One detail is missing from the announcement, and it is the one that would tell the public how seriously the regulator views the defect. The FDA sorts recalls into three tiers through a health hazard evaluation, with Class I reserved for cases involving a reasonable probability of serious adverse health consequences or death, Class II for temporary or medically reversible harm, and Class III for defects unlikely to cause adverse health consequences.

No such classification appears in the company announcement. The FDA's drug recall database currently lists the American Regent recall without a classification, so claims from automated recall-tracking websites that it is Class I should not be presented as an FDA-confirmed classification.

Other basic facts remain undisclosed. The announcement does not say how many individual vials are affected across the three lots, nor does it break down how much of the product went to hospitals as opposed to other purchasers.

Adverse events can be reported through the FDA's MedWatch programme or by calling 1-800-332-1088.

No patient has been reported harmed so far, and the recall was carried out with the knowledge of the FDA, which posts such announcements as a public service and states that it does not endorse the company or product.